Reference : Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous...
Scientific journals : Letter to the editor
Human health sciences : Hematology
http://hdl.handle.net/2268/179794
Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
English
JASPERS, Aurélie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Baron, Frédéric mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Maertens, Johan [University Hospital Gasthuisberg, Leuven, Belgium > Clinical Hematology > Acute Leukemia & Stem Cell Transplantation Unit > >]
DE PRIJCK, Bernard mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Schots, Rik [Universitair Ziekenhuis Brussel, Belgium > Department of Clinical Hematology and Stem Cell Laboratory > > >]
Bonnet, Christophe mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
HAFRAOUI, Kaoutar mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
WILLEMS, Evelyne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
SERVAIS, Sophie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
FILLET, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Jul-2015
American Journal of Hematology
Wiley Liss, Inc.
90
7
E133-4
Yes (verified by ORBi)
International
0361-8609
1096-8652
New York
NY
[en] autologous hematopoietic cell transplantation ; Darbepoetin alpha ; survival ; erythropoietin therapy ; intravenous iron
http://hdl.handle.net/2268/179794
10.1002/ajh.24013

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Jaspers - AJH 2015.pdfPublisher postprint225.22 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.